share_log

Dr. Reddy's Launches Drug-Free Migraine Management Device Nerivio In Europe Following Successful Launch In India

Dr. Reddy's Launches Drug-Free Migraine Management Device Nerivio In Europe Following Successful Launch In India

继印度成功推出后,雷迪博士在欧洲推出了无毒偏头痛管理设备Nerivio
Benzinga ·  04/10 07:08

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, hereafter referred to as ", Dr. Reddy', s", )), a global pharmaceutical company, announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in Germany through its step-down subsidiary betapharm. The launch marks the company's entry into digital therapeutics in Europe. Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

全球制药公司雷迪博士实验室有限公司(BSE:500124,纽约证券交易所:DRREDDY,纽约证券交易所代码:RDY,NSEIFSC:DRREDDY,以下简称 “,雷迪博士,s”,))宣布通过其下台子公司betapharm在德国推出无药非侵入性偏头痛管理可穿戴设备Nerivio。此次推出标志着该公司进入欧洲数字疗法。Nerivio 已获得美国食品药品监督管理局 (USFDA) 的批准,并在欧洲获得了 CE 标志认证。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发